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Abstract Nedd2 belongs to a family of mammalian cysteine 
proteases which share similarity with the Caenorhabditis elegans 
cell death protein, Ced-3. Overexpression of Nedd2 has been 
shown to induce apoptosis in mammalian cells but in the absence 
of a specific known inhibitor, it remains to be seen whether this 
represents cytotoxic effects of the Nedd2 protease or the specific 
activation of an apoptotic pathway. The present work shows that 
the factor-dependent cell line FDC-P1 expressing mouse anti- 
sense Nedd2 mRNA, exhibits significant inhibition of cell death 
upon removal of the cytokines, thus providing evidence for a 
direct role of Nedd2 in mediating apoptosis. 
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1. Introduction 
Apoptosis or programmed cell death (PCD) is an active proc- 
ess of cell suicide characterised by a distinct set of morpholog- 
ical events involving plasma membrane blebbing, loss of cell 
volume, nuclear condensation, and fragmentation of DNA at 
nucleosomal intervals [1,2]. Cell death by apoptosis i  essential 
to remove unwanted cells and to regulate cell number during 
development and homeostasis in metazoans [3,4]. Much of the 
recent information on the molecular egulation of apoptosis 
has come from the genetic analysis of the nematode Caenorhab- 
ditis elegans [5]. Two genes, ced-3 and ced-4, required for the 
developmental cell death in the worm have been cloned in the 
recent years [5]. While ced-4 encodes aputative calcium binding 
protein, nothing is known about its function and no mammal- 
ian homologues of the Ced-4 protein have yet been discovered 
[6]. On the other hand, cloning of ced-3 indicated that its prod- 
uct is similar to interleukin-lfl converting enzyme (ICE) [7], a 
cysteine protease required for the proteolytic activation of IL- 
lfl [8-10], and the product of a developmentally regulated 
mouse gene Nedd2 [11,12]. Another Ced-3 homologue named 
CPP32 has been recently cloned [13]. In addition, priCE, a 
cysteine protease activity, distinct from ICE has been identified 
in apoptotic ell extracts [14]. There is now growing evidence 
suggesting a central role for ICE-family of cysteine proteases 
as effectors of PCD [15]. 
The evidence for the role of these ICE-like mammalian pro- 
teins in apoptosis is largely derived from the observation that 
the overexpression f ICE, Nedd2 and CPP32 induces apopto- 
sis in eukaryotic ells [12,13,16,17]. These experiments are in- 
conclusive since the overexpression f a protease might have 
cytotoxic effects irrespective of its role in the mediation of 
apoptosis. More direct evidence for a role of ICE and priCE 
in apoptosis has come the from the inhibitor studies. For exam- 
ple, CrmA, a viral serpin inhibitor of ICE [18] has been shown 
to inhibit neuronal cell death induced by deprivation of nerve 
growth factor [19]. However, specificity of CrmA inhibition is 
unknown and it is possible that it also acts on other ICE-like 
proteases. Try-Val-Ala-Asp-chloro-methylketone (YVAD- 
CMK), an ICE and priCE inhibitor is also known to inhibit 
apoptosis associated morphological changes in an in vitro sys- 
tem [14,20]. Yet again, YVAD-CMK is not specific for any one 
of these proteases and probably acts on all ICE homologs 
requiring Asp residue in P1 position of the substrate. From the 
studies published so far, it is unclear whether one or more of 
the ICE-like proteases are required in a single apoptotic path- 
way or whether these proteins are functionally redundant. 
Despite much in vitro experimental evidence implicating ICE 
in apoptosis, mice lacking functional ICE gene are overtly nor- 
mal and show no apparent defect in dexamethasone- or ionising 
radiation-induced apoptosis of thymocytes [21]. However, 
ICE(-~-) mice are resistant to apoptosis induced by 
Fas antibody [22]. This suggests that the in vivo role of ICE may 
be limited to Fas mediated apoptosis and thus, various ICE-like 
proteases may act in different apoptotic pathways. To establish, 
which of the ICE-like proteins are required in a particular 
apoptotic pathway, experiments involving functional inactiva- 
tion of the individual members would be required. This can be 
achieved by gene targetting, as has been done with ICE, and 
by using specific inhibitors of individual proteins. 
In the absence of a known specific inhibitor of Nedd2 func- 
tion, in the present work, we have used antisense mRNA ex- 
pression as a means to modulate the levels of Nedd2 to study 
whether it plays a direct role in apoptosis. We show that expres- 
sion of Nedd2 antisense mRNA in a factor-dependent murine 
hematopoietic cell line FDC-P1 [23], significantly inhibited the 
apoptosis of these cells under cytokine deprived conditions. 
This provides a compelling evidence that Nedd2 protein is 
required for apoptosis in FDC-P1 cells, and its inhibition alone 
can suppress cell death. 
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2. Materials and methods 
2.1. Expression constructs and transfection fcells 
The construction of Nedd2 expression vectors has been described 
before [12]. In pCXN2-N2 (Nedd2 sense xpression construct), the 
cDNA containing the entire coding region of Nedd2 was released from 
clone pMS N2.4 and inserted ownstream of the chicken fl-actin pro- 
moter in pCXN2 vector [24]. The antisense construct (pCXN2-N2AS) 
contained a 1.0 kb SalI fragment of the clone pMS N2.4, representing 
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the 5'-end of the mouse Nedd2 mRNA, in antisense orientation [12]. 
FDC-P1 cells were routinely maintained in DMEM supplemented with 
10% fetal calf serum (FCS) and 40 units/ml of murine GM-CSF. For 
each transfection, 4 #g of plasmid DNA in 0.5 ml OPTIMEM (Life 
Technologies) was mixed with 10 ,ul of Lipofectamine (Life Technolo- 
gies) in 0.5 ml Optimem and incubated at room temperature for 30 min. 
FDC-P1 cells (106/transfection) were washed once in Optimem, resus- 
pended in DNA/Lipofectamine mix, supplemented with 40 units/ml 
GM-CSF, and plated into a 6-well dish. After 6 h incubation at 37°C, 
each well was fed with 3 ml of Optimem containing 20% FCS and 40 
units/ml GM-CSF. The following day, cells were pelleted, washed and 
plated in DMEM supplemented with 10% FCS, 40 units/ml GM-CSF 
and 1 mg/ml G-418. Transfected cells were selected for antibiotic re- 
sistance for 2-weeks prior to cloning. Cloning of the transfected cells 
was done in methyl cellulose/IMDM semisolid medium [25]. Approxi- 
mately 200 cells were mixed with methyl cellulose/IMDM mix supple- 
mented with 10% FCS, 1 mg/ml G-418 and 50 units/ml GM-CSF, and 
plated in 60 mm dishes. Well isolated colonies were picked after 7-14 
days incubation and maintained in DMEM with FCS, GM-CSF and 
1 mg/ml G-418. 
2.2. RNA isolation and analysis 
Poly(A) ÷ RNA was isolated from cultured cells using the Fast Track 
kit (Invitrogen) or by oligo(dT) batch absorption [26]. Approximately 
2.0 #g of poly(A) + RNA samples were electrophoresed on 1.2% aga- 
rose/2.2 M formaldehyde gels, transferred to Biodyne A membrane 
(Pall) and hybridized to probes labelled with [~-32p]dCTP by random 
priming using Klenow fragment of DNA polymerase [26]. Mouse 
Nedd2 probe was a 2.2 kb BamHI/XhoI fragment of the clone MS N2.4 
representing the entire coding region of the cDNA [10]. Human 
NEDD2 (Nedd2 and NEDD2 are approved gene symbols for mouse and 
human homologues, respectively) probe was derived as a 0.8 kb EeoRI 
fragment of the clone Hb N2.3 [27]. 
2.3. Cell death experiments 
Cells were washed in DMEM supplemented with FCS three times 
and resuspended at2 × 10 6 cells/ml in the same medium. One-hundred 
#1 aliquots were incubated in 96-well plates for the desired length of 
time. In the control experiments, cells washed in a similar way were 
resuspended in medium containing 40 units/ml of GM-CSF or 100 
units/ml IL-3 to account for the cell death which may occur during 
washing procedures. Equal volumes of cell suspension were mixed with 
0.8% Trypan blue and dye positive and negative cells were counted 
using a hemocytometer. In these experiments, at time zero (soon after 
the washing steps), typically more than 90% cells were viable as deter- 
mined by Trypan blue dye exclusion. In all cell death experiments, cells 
were examined for apoptosis-associated morphological changes and 
DNA fragmentation, asdescribed previously [12]. To adapt FDC-P1 
transfectants o IL-3, cells were grown for a week in the medium 
supplemented with 40 units/ml GM-CSF and 100 units/ml IL-3, then 
switched to medium with IL-3 alone. Cells were maintained in IL-3 
medium for atleast 2 weeks prior to cell death experiments. 
3. Results and discussion 
Factor-dependent hematopoietic cell lines have been exten- 
sively used to study PCD (e.g. [28]). Upon removal of cytokines, 
these cells undergo rapid cell death by apoptosis. Since there 
is no information available on the expression of Nedd2 in hema- 
topoietic ells, we first examined a number of human cell lines 
by Northern blot analysis for NEDD2 mRNA.  All cell types 
analyzed expressed moderate levels of the 4.2 kb human 
NEDD2 transcript (Fig. 1). These cell lines represented several 
human myeloid and lymphoid lineages and included B-cell lym- 
phoblasts (Balm), erythroleukemia (HELdr, HEL 900), mast 
cell (HMC-1), T-cell lymphoblasts (Molt4, CCRF-CEM),  
megakaryocytes (Mo7e), myelomonocytes (RC2A) and promy- 
elocytes (HL60). This widespread expression in hematopoietic 
cells suggests that Nedd2 has an important role as a mediator 
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Fig. 1. Expression of NEDD2 in various human hematopoietic cell 
lines. Each lane contained approximately 2 #g of poly(A) ÷ RNA iso- 
lated from the indicated cell line. Blots were hybridized with a human 
NEDD2 cDNA probe [27] which detected a single 4.2 kb transcript in 
all cell lines. The quality and quantity of RNA preparions were deter- 
mined by ethidium bromide staining and hybridization to a glyceralde- 
hyde 3-phosphate dehydrogenase probe (not shown). Data are derived 
from two different gels. 
Murine myeloid progenitor cell line FDC-P1, which also 
expressed moderate levels of Nedd2 mRNA (Fig. 2) was chosen 
for the antisense studies using mouse Nedd2 cDNA expression 
constructs, because of its apoptosis response has been well 
characterized [29,30]. This cell line can be maintained with 
either GM-CSF or IL-3 and upon removal of the factor under- 
goes apoptosis within 1 2 days [29,30]. FDC-P1 cells were 
transfected by lipofection with a mammalian expression vector 
(pCXN2), the vector carrying Nedd2 cDNA containing entire 
coding region in sense orientation (PCXN2-N2), or 5'-1.0 kb 
fragment of the Nedd2 cDNA in antisense orientation (pCXN2- 
N2AS). Transfected cells were selected with G-418 for two 
weeks and antibiotic resistant cells were then cloned by plating 
into semisolid medium. In methyl cellulose semisolid medium, 
the colony size and morphology of antisense and vector-trans- 
fected cell were similar; however, cells transfected with Nedd2 
sense construct formed much smaller colonies (10-20% in di- 
ameter). But in liquid cultures the growth rates of cells trans- 
fected with either vector, sense or antisense were comparable. 
The reasons for these variations in growth characteristics of 
Nedd2 sense-transfected cells are not known. 
Several individual clones were analysed by Northern blotting 
for the expression of introduced cDNA. Comparable levels of 
expression was detected in various clones transfected with a 
particular expression construct, although the expression of 
mRNA from introduced plasmids was always far greater for 
the antisense than the sense (Fig. 2). This is consistent with the 
fact that overexpression of Nedd2 induces apoptosis in various 
cell lines [12,16] and FDC-P1 cells expressing Nedd2 over a 
certain threshold are likely to undergo apoptosis. Thus, antibi- 
otic selection for the transfected cells would favour transfec- 
tants which express relatively low levels of Nedd2. In all the 
sense-transfected clones, the ratio of transfected versus en- 
dogenous expression was 2-3, which probably reflects a meas- 
ure of tolerance of these cells. The Nedd2 antisense-transfected 
cells on the other hand, show levels of RNA expression atleast 
20 times the endogenous Nedd2 transcript (Fig. 2). 
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Fig. 2. Expression of Nedd2 in transfected FDC-P1 cells. Cloned trans- 
fected cells were used for the isolation of poly(A) ÷ RNA. Each lane 
contains approximately 2 pg of poly(A) ÷ RNA. Blots were hybridized 
with a mouse Nedd2 probe. The arrow on the left indicate the 3.5 kb 
endogenous transcript while the ones on the right indicate the tran- 
scripts derived from introduced expression constructs. The transfected 
Nedd2 sense construct produces a transcript of approximately 2.3 kb, 
while the antisense construct generates a 1.3 kb mRNA species. Addi- 
tional transcripts seen in antisense tranfected cells most likely result 
from aberrant splicing and/or termination [12]. 
Several vector-, sense- and antisense-transfected clones were 
analysed for the cell death induced in the absence of factor and 
the results for some are shown in Fig. 3. In general, there was 
no significant variations between various clones derived from 
cells tranfected with an individual expression construct. Con- 
trol FDC-P1 cells transfected with the empty vector showed 
typical response with most (> 90%) cells undergoing apoptosis 
within 24 h of the removal of GM-CSF (Fig. 3A). The cells 
transfected with the sense Nedd2 showed similar patterns of cell 
death when plated in factor-free medium. On the other hand, 
clones expressing antisense Nedd2 showed significant inhibition 
of cell death under similar conditions (Fig. 3A). After 24 h in 
factor-free medium, while less than 10% of the vector-trans- 
fected control cells were Trypan blue negative, approximately 
40% of the antisense expressing cells excluded the dye. Morpho- 
logical observations confirmed that dye-excluding cells exhib- 
ited no characteristic features of apoptosis (data not shown). 
In all experiments, the cells washed and replated in GM-CSF 
containing medium did not show any significant cell death 
(data not shown). To analyse whether IL-3 dependent FDC-P1 
cells show similar effects, transfected clones were adapted to 
IL-3 for at least two weeks and subjected to IL-3-free condi- 
tions. Again, the clones expressing antisense Nedd2 showed 
significant inhibition of cells death (Fig. 3B). These results 
clearly indicate that Nedd2 antisense xpression suppresses/ 
delays the apoptosis induced by the deprivation of either GM- 
CSF or IL-3 in FDC-P1 cells. 
The levels of endogenous Nedd2 mRNA did not appear to 
be significantly altered in the cells expressing antisense. It is 
therefore likely that antisense xpression inhibits the transla- 
tion of endogenous Nedd2 mRNA. Because of the unavailabil- 
ity of a suitable antibody against Nedd2, it was not possible to 
check the levels of endogenous Nedd2 in antisense-transfected 
cells. Nevertheless, the data presented here provide a strong 
evidence for a direct role for Nedd2 in apoptosis. It also sug- 
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Fig. 3. Inhibition of cell death by antisense Nedd2 expression. 
Tranfected cloned cell were maintained ineither GM-CSF (A) or IL-3 
(B) and subjected to cytokine-free conditions to induce apoptosis as 
described in section 2. At indicated time after plating in factor-free 
medium, cells were mixed with Trypan blue and both stained and dye 
excluding cells counted. Each experiment was done in triplicate and the 
data from a single experiment is plotted. Similar esults were obtained 
in at least six independent experiments employing several different 
clones. Vector-transfected clone 2 (o); sense Nedd2-transfected clone 3 
(o); antisense Nedd2- transfected clone 5 (=) and clone 9 (•). 
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inhibit cell death. In addition to Nedd2, low level ICE expres- 
sion was also detected in FDC-P1 cells (data not shown). 
mRNA for CPP32 has been shown to be highly expressed in 
several cell lines of hematopoietic lineages [14]. Since Nedd2 
cDNA sequence shares only partial similarity with ICE and 
CPP32 [10,12,13], antisense Nedd2 expression is unlikely to 
alter the levels of endogenous ICE and CPP32 proteins. In 
DNA and RNA blot analyses, probes derived from Nedd2 
cDNA, do not detect other homologues [12]. Furthermore, no 
changes in the ICE mRNA and protein levels were observed 
in FDC-P1 clones expressing the antisense Nedd2 transcript 
(data not shown). Inhibition of apoptosis by the suppression 
of Nedd2 suggests that this protease constitutes a component 
of the cell death machinery in FDC-P1 cells. However, we 
cannot rule out the involvement of the other ICE family mem- 
bers as the expression of Nedd2 antisense only partially inhib- 
ited the apoptosis of FDC-P1 cells. 
An alternately spliced form of Nedd2 mRNA which encodes 
a truncated form of protein, Nedd2s (Ich-ls in [16]) has been 
shown to act as a negative regulator of apoptosis in Rat-1 cells 
[16]. As the sequences of Nedd2 and Nedd2s mRNA are identi- 
cal except for a 61 bp region derived from alternate splicing in 
Nedd2s, the antisense xpression is likely to affect the levels of 
both forms of proteins. The mRNA for Nedd2s is low but 
detectable in FDC-P1 cells, however we have failed to see any 
effects on the survival of FDC-P1 cells transfected with Nedd2s 
(S.K. et al., unpublished ata). These observations suggest hat 
Nedd2s is unlikely to play a major role in the regulation of 
apoptosis in FDC-P1 cells. 
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